Other than saroglitazar, elafibranor, a PPAR / agonist, was tested in a 1-year phase II RCT involving 274 subjects with biopsy-proven NASH, 107 of whom were diabetic: using a modified post hoc primary endpoint, elafibranor resolved NASH in a significant percentage of patients, without worsening of fibrosis, and ameliorated the hepatic and metabolic profile [67]
Talk to a clinician about evidence-based options
CrossRef Beyond Discrete Diagnoses: Conceptualizing Obesity-associated Metabolic Disorders as a Unified, Dynamic Continuum Cong Xie, Yulian Yuan, Yunjing Wang, Cong Qi, Wei Wang, Chuan An, Aifeila Aikepaer, Yaofu Zhang, Ge Zhang, Xingzhong Feng, Huijuan Gao Current Obesity Reports .2025;[Epub] CrossRef Immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: The critical role of subgroup analyses Tingfeng Huang, Jia-Hao Law, Ningqi Pang, Shichuan Tang iLIVER .2025
Many people report feeling more focused, clear-headed, and in a better mood after receiving B12 injections
Roncal-Jimenez C et al